Bayer: studies confirm efficacy of Xarelto

(CercleFinance.com) - Bayer has announced that results from an extension of the COMPASS study support the efficacy of dual pathway inhibition (DPI) therapy with rivaroxaban (Xarelto) as an adjunct to aspirin in patients with coronary artery disease and/or peripheral artery disease.


In addition, another study (XATOA) provides further evidence of the benefit of dual pathway inhibition (DPI) for patients with vascular disease at high risk of cardiovascular (CV) events in routine clinical practice.

These studies reinforce the findings of the COMPASS study which confirmed - back in 2017 - that Xarelto 2.5 mg twice daily, in combination with aspirin 100 mg once daily, reduced the risk of stroke, cardiovascular death and heart attack by 24% (relative risk reduction) in patients with chronic coronary artery disease and/or peripheral arterial disease.



Copyright (c) 2022 CercleFinance.com. All rights reserved.